Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions

Provided herein are compositions, methods and uses of humanin or a humanin analog, for example, in treating a subject with humanin or a humanin analog, in part, to reduce, decrease, or inhibit cardiotoxicity caused or induced by an anti-cancer or anti-tumor therapeutic agent, or to protect or preser...

Full description

Saved in:
Bibliographic Details
Main Authors Swerdloff, Ronald S, Wang, Christina, Lue, YanHe
Format Patent
LanguageEnglish
Published 06.10.2020
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Provided herein are compositions, methods and uses of humanin or a humanin analog, for example, in treating a subject with humanin or a humanin analog, in part, to reduce, decrease, or inhibit cardiotoxicity caused or induced by an anti-cancer or anti-tumor therapeutic agent, or to protect or preserve cardiac function in the presence of an anti-tumor or anti-cancer therapeutic agent. In some aspects, humanin or humanin analogs, alone or in combination with another cardioprotective agent such as Dexrazoxane are used in combination with a chemotherapeutic agent to treat a hyperproliferative disease or disorder.
Bibliography:Application Number: US201815916204